Literature DB >> 3220579

Clinical features of hepatitis delta virus infection in a northern Italian area.

G Pasetti1, C Calzetti, A Degli Antoni, C Ferrari, A Penna, F Fiaccadori.   

Abstract

Expression of hepatitis delta virus (HDV) markers was investigated in sera from 310 patients with acute hepatitis, 63 chronic hepatitis B surface antigen (HBsAg) carriers and 76 drug addicts positive for at least one serological hepatitis B virus (HBV) marker. Acute HDV infection occurred in 17.1% of the patients with acute hepatitis. Among 40 cases of coinfection, hepatitis was severe in ten and fulminant in three. Only two of the 13 superinfected patients showed a severe hepatitis, but a high percentage (78%) of them developed chronic hepatitis one year after HDV infection. Also in our area parenteral drug addiction represents the main factor of risk for HDV infection. The high prevalence of HDV infection in our area points to the necessity for serological screening for HDV markers in patients with acute and chronic hepatitis.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3220579     DOI： 10.1007/bf01644544

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  16 in total

1.  The hepatitis delta (delta) virus possesses a circular RNA.

Authors:  A Kos; R Dijkema; A C Arnberg; P H van der Meide; H Schellekens
Journal:  Nature       Date:  1986 Oct 9-15       Impact factor: 49.962

2.  Worldwide epidemiology and modes of transmission of delta hepatitis.

Authors:  A R Zanetti; A Ponzetto; B Forzani; C Hele
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

3.  Prevalence and clinical effects of delta agent. Infections in Norwegian population subgroups.

Authors:  J C Siebke; B von der Lippe; B G Hansson; E Nordenfelt; M Degré
Journal:  Scand J Infect Dis       Date:  1986

4.  Epidemiology of HBV-associated delta agent: geographical distribution of anti-delta and prevalence in polytransfused HBsAg carriers.

Authors:  M Rizzetto; R H Purcell; J L Gerin
Journal:  Lancet       Date:  1980-06-07       Impact factor: 79.321

Review 5.  Experimental hepatitis delta virus infection in the chimpanzee.

Authors:  R H Purcell; W C Satterfield; K F Bergmann; A Smedile; A Ponzetto; J L Gerin
Journal:  Prog Clin Biol Res       Date:  1987

6.  Influence of delta infection on severity of hepatitis B.

Authors:  A Smedile; P Farci; G Verme; F Caredda; A Cargnel; N Caporaso; P Dentico; C Trepo; P Opolon; A Gimson; D Vergani; R Williams; M Rizzetto
Journal:  Lancet       Date:  1982-10-30       Impact factor: 79.321

7.  Epidemiologic patterns of infection with the hepatitis B virus-associated delta agent in Italy.

Authors:  A Smedile; C Lavarini; P Farci; S Aricò; G Marinucci; P Dentico; G Giuliani; A Cargnel; C Del Vecchio Blanco; M Rizzetto
Journal:  Am J Epidemiol       Date:  1983-02       Impact factor: 4.897

8.  Delta virus infection and severe hepatitis. An epidemic in the Yucpa Indians of Venezuela.

Authors:  S C Hadler; M De Monzon; A Ponzetto; E Anzola; D Rivero; A Mondolfi; A Bracho; D P Francis; M A Gerber; S Thung
Journal:  Ann Intern Med       Date:  1984-03       Impact factor: 25.391

9.  Serological diagnosis of acute delta hepatitis.

Authors:  M Buti; R Esteban; R Jardí; J I Esteban; J Guardia
Journal:  J Med Virol       Date:  1986-01       Impact factor: 2.327

10.  Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome.

Authors:  F Caredda; E Rossi; A d'Arminio Monforte; L Zampini; T Re; B Meroni; M Moroni
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226
View more
  2 in total

1.  Acute hepatitis B and hepatitis D co-infection in the Stockholm region in the 1970s and 1980s--a comparison.

Authors:  G Lindh; L Mattsson; M von Sydow; O Weiland
Journal:  Infection       Date:  1990 Nov-Dec       Impact factor: 3.553

Review 2.  Pathogenesis of and New Therapies for Hepatitis D.

Authors:  Christopher Koh; Theo Heller; Jeffrey S Glenn
Journal:  Gastroenterology       Date:  2018-10-18       Impact factor: 22.682
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.